Results 121 to 130 of about 28,830 (248)

Safety and Tolerability of Xanthohumol in Adults With Crohn's Disease: Results of a Triple‐Masked, Randomized, Placebo‐Controlled Phase 2 Trial

Molecular Nutrition &Food Research, Volume 70, Issue 6, 29 March 2026.
Adults with active Crohn's disease (n = 20) received 24 mg/day of xanthohumol (XN), a bioactive compound derived from Humulus lupulus (hops), for 8 weeks. The study evaluated safety and tolerability through clinical laboratory measures, adverse events, vital signs, anthropometrics, health−related quality of life, and adherence.
Ryan Bradley, Carina A. Staab, Paige E. Jamieson, Blake O. Langley, Thomas O. Metz, Jan F. Stevens   +5 more
wiley   +1 more source

Proteolytic cleavage of the rat heparan sulfate 6-O-endosulfatase SulfFP2 by furintype proprotein convertases [PDF]

, 2010
journal ...
KEINO-MASU Kazuko, MASU Masayuki, Nagamine Satoshi, Shiomi Kensuke   +3 more
core   +1 more source

Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors

International Journal of Biological Sciences, 2010
Proprotein convertases are enzymes that proteolytically cleave protein precursors in the secretory pathway to yield functional proteins. Seven mammalian subtilisin/Kex2p-like proprotein convertases have been identified: furin, PC1, PC2, PC4, PACE4, PC5 ...
Sun Tian, Wu Jianhua
doaj  

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9

Journal of Lipid Research, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has gained attention as a key regulator of serum low density lipoprotein cholesterol (LDL-C) levels. This novel protease causes the degradation of hepatic low density lipoprotein receptors. In humans,
Holly E. Careskey, R. Aleks Davis, William E. Alborn, Jason S. Troutt, Guoqing Cao, Robert J. Konrad   +5 more
doaj   +1 more source

Letter to the Editor in Response to “A novel index for diagnosis of type 2 diabetes mellitus: Cholesterol, high density lipoprotein, and glucose (CHG) index”

Journal of Diabetes Investigation, EarlyView.
Ying Li, Lei Jin
wiley   +1 more source

Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort

Obesity, Volume 34, Issue 3, Page 579-587, March 2026.
ABSTRACT Objective This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet‐Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS).
Jesús Argente, Andrea M. Haqq, Jan Luca Schorfheide, Nicolas Touchot, Caroline Huber, Urs Wiedemann, Jeremy Pomeroy, on behalf of the Phase 3 BBS Trial Investigators, Wendy Chung, Karine Clément, Hélène Dollfus, Elizabeth Forsythe, Robert M. Haws, Gabriel Á. Martos‐Moreno, Christine Poitou, Jack A. Yanovski   +15 more
wiley   +1 more source

Therapeutic Strategies for Hypercholesterolemia

healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses
A high cholesterol level in the blood is associated with an increased risk of atherosclerosis and its related conditions such as heart attack and stroke.
Georg Noll, André Linka, Thomas Lüscher, Isabella Sudano   +3 more
doaj   +1 more source

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, Volume 183, Issue 5, Page 990-1008, March 2026.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

The effects of cholesterol-lowering drugs on neurocognitive function: systematic review and meta analysis

Frontiers in Neurology
ObjectiveTo investigate if cholesterol-lowering drugs exert effects on neurocognitive function.MethodsWe searched Pubmed, Embase and Cochrane Libarary from inception to March 23rd, 2023, and searched clinicaltrials.gov on January 23rd, 2024.
Kaiwei Li, Kaiwei Li, Ying Li, Xia Jiang, Ye Zhu, Ye Zhu   +5 more
doaj   +1 more source

Treg cells retain stable lineage commitment during pregnancy in mice after late gestation inflammatory challenge

Immunology &Cell Biology, Volume 104, Issue 3, Page 276-311, March 2026.
In this study, we used Foxp3‐fatemapping mice to examine the cell lineage stability of Treg cells in pregnancy. Ex‐Foxp3 cells were identified in gestational tissues. However, Treg cells retained lineage stability with no increased ex‐Foxp3 generation, regardless of inflammatory challenges that induce preterm birth.
Kerrie L Foyle, Ella S Green, Jessie R Walker‐Rogers, Ha M Tran, David M Olson, Lachlan M Moldenhauer, Sarah A Robertson   +6 more
wiley   +1 more source